U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H21NO4
Molecular Weight 327.3743
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NALOXONE

SMILES

[H][C@@]12OC3=C4C(C[C@H]5N(CC=C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3O

InChI

InChIKey=UZHSEJADLWPNLE-GRGSLBFTSA-N
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H21NO4
Molecular Weight 327.3743
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Naloxone, sold under the brand name Narcan among others, is a medication used to block the effects of opioids, especially in overdose. Naloxone has an extremely high affinity for μ-opioid receptors in the central nervous system (CNS). Naloxone is a μ-opioid receptor (MOR) inverse agonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. Naloxone also has an antagonist action, though with a lower affinity, at κ- (KOR) and δ-opioid receptors (DOR). If administered in the absence of concomitant opioid use, no functional pharmacological activity occurs (except the inability for the body to combat pain naturally). In contrast to direct opiate agonists, which elicit opiate withdrawal symptoms when discontinued in opiate-tolerant people, no evidence indicates the development of tolerance or dependence on naloxone. The mechanism of action is not completely understood, but studies suggest it functions to produce withdrawal symptoms by competing for opiate receptor sites within the CNS (a competitive antagonist, not a direct agonist), thereby preventing the action of both endogenous and xenobiotic opiates on these receptors without directly producing any effects itself. When administered parenterally (e.g. intravenously or by injection), as is most common, naloxone has a rapid distribution throughout the body. The mean serum half-life has been shown to range from 30 to 81 minutes, shorter than the average half-life of some opiates, necessitating repeat dosing if opioid receptors must be stopped from triggering for an extended period. Naloxone is primarily metabolized by the liver. Its major metabolite is naloxone-3-glucuronide, which is excreted in the urine. Naloxone is useful both in acute opioid overdose and in reducing respiratory or mental depression due to opioids. Whether it is useful in those in cardiac arrest due to an opioid overdose is unclear. Naloxone is poorly absorbed when taken by mouth, so it is commonly combined with a number of oral opioid preparations, including buprenorphine and pentazocine, so that when taken orally, just the opioid has an effect, but if misused by injecting, the naloxone blocks the effect of the opioid. In a meta-analysis of people with shock, including septic, cardiogenic, hemorrhagic, or spinal shock, those who received naloxone had improved blood flow. Naloxone is also experimentally used in the treatment for congenital insensitivity to pain with anhidrosis, an extremely rare disorder (one in 125 million) that renders one unable to feel pain or differentiate temperatures. Naloxone can also be used as an antidote in overdose of clonidine, a medication that lowers blood pressure.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.3 nM [IC50]
49.8 nM [IC50]
138.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NARCAN

Approved Use

Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only.

Launch Date

4.0348799E10
Primary
NARCAN

Approved Use

Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only.

Launch Date

4.0348799E10
Primary
NARCAN

Approved Use

Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only.

Launch Date

4.0348799E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.09 ng/mL
10 mg/kg single, nasal
dose: 10 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.87 ng/mL
0.4 mg single, intramuscular
dose: 0.4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.62 ng/mL
8 mg single, nasal
dose: 8 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.83 ng/mL
4 mg single, nasal
dose: 4 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.1 ng × min/mL
10 mg/kg single, nasal
dose: 10 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.68 ng × h/mL
0.4 mg single, intramuscular
dose: 0.4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15 ng × h/mL
8 mg single, nasal
dose: 8 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 ng × h/mL
4 mg single, nasal
dose: 4 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
28.2 min
10 mg/kg single, nasal
dose: 10 mg/kg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.2 h
0.4 mg single, intramuscular
dose: 0.4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.1 h
8 mg single, nasal
dose: 8 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NALOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 mg single, intramuscular
Dose: 0.8 mg
Route: intramuscular
Route: single
Dose: 0.8 mg
Sources:
healthy, 23.8 years (range: 22.6–25 years)
n = 12
Health Status: healthy
Age Group: 23.8 years (range: 22.6–25 years)
Sex: M+F
Population Size: 12
Sources:
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Disc. AE: Hypotension, Bradycardia...
Other AEs: Nausea, Emesis...
AEs leading to
discontinuation/dose reduction:
Hypotension (3 patients)
Bradycardia (2 patients)
Myoclonus (1 patient)
Hypertension (1 patient)
Other AEs:
Nausea (32%)
Emesis (5%)
Seizures (5%)
Headache (5%)
Confusion (5%)
Agitation (3%)
Sources:
8 mg single, intranasal
Dose: 8 mg
Route: intranasal
Route: single
Dose: 8 mg
Sources:
healthy, adult
n = 28
Health Status: healthy
Age Group: adult
Population Size: 28
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension 1 patient
Disc. AE
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Myoclonus 1 patient
Disc. AE
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Bradycardia 2 patients
Disc. AE
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Hypotension 3 patients
Disc. AE
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Agitation 3%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Nausea 32%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Confusion 5%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Emesis 5%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Headache 5%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
Seizures 5%
160 mg/m2 single, intravenous (starting)
Highest studied dose
Dose: 160 mg/m2
Route: intravenous
Route: single
Dose: 160 mg/m2
Sources:
unhealthy, 35-85 years
n = 38
Health Status: unhealthy
Condition: acute ischemic stroke
Age Group: 35-85 years
Population Size: 38
Sources:
PubMed

PubMed

TitleDatePubMed
Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice.
1992 Aug
Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain.
1992 Jan
The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat.
1992 Mar 20
Neurotransmitter-mediated open-field behavioral action of CGRP.
1999
Effects of naloxone on nitrous oxide actions in healthy volunteers.
1999 Dec
Repressive/defensive coping, endogenous opioids and health: how a life so perfect can make you sick.
1999 Jan 18
[The discriminative stimulus properties of naloxone during dissociative learning in a Y maze in morphine-dependent rats].
1999 Jan-Feb
G-protein-coupled receptor heterodimerization modulates receptor function.
1999 Jun 17
Seizure and electroencephalographic changes in the newborn period induced by opiates and corrected by naloxone infusion.
1999 Mar
Morphine inhibits human microglial cell production of, and migration towards, RANTES.
2000
The effect of spinal ibuprofen on opioid withdrawal in the rat.
2000 Aug
A peripheral, intracerebral, or intrathecal administration of an opioid receptor antagonist blocks illness-induced hyperalgesia in the rat.
2000 Dec
Hypertensive crisis and myocardial infarction following massive clonidine overdose.
2000 May
Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine.
2000 Sep
Effects of contextual or olfactory cues previously paired with morphine withdrawal on behavior and pain sensitivity in the rat.
2001 Aug
Role of nitric oxide in catalepsy and hyperthermia in morphine-dependent rats.
2001 Dec
Naloxone improves arterial blood pressure and hypoxic ventilatory depression, but not survival, of rats during acute hypoxia.
2001 Mar
Effects of Ferula gummosa Boiss. fractions on morphine dependence in mice.
2001 Sep
Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome.
2002 Jul
Increase in serum level of interleukin-1 alpha mediates morphine anti-inflammatory effect in carrageenan-induced paw oedema in mice.
2002 Jul 21
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
2002 Oct
Naloxone increases pain induced by topical capsaicin in healthy human volunteers.
2002 Sep
Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area.
2003 Jun
Heroin addicts to receive CPR training and Narcan.
2003 May
Decrease of morphine-induced reward effects and withdrawal symptoms in mice overexpressing gamma-aminobutyric acid transporter I.
2003 Nov 15
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.
2003 Sep 5
Influence of sweet tasting solutions on opioid withdrawal.
2004 Dec 15
Adverse events after naloxone treatment of episodes of suspected acute opioid overdose.
2004 Feb
Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2+/calmodulin-dependent signal cascade.
2004 Jul 9
A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase.
2004 Jul 9
Magnesium influence on morphine--induced pharmacodependence in rats.
2004 Mar
Testosterone and luteinizing hormone responses to naloxone help predict sexual performance in rams.
2004 Nov
Potentiated startle and hyperalgesia during withdrawal from acute morphine: effects of multiple opiate exposures.
2004 Nov
Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system.
2004 Nov 19
Effects of L-745,870, a dopamine D4 receptor antagonist, on naloxone-induced morphine dependence in mice.
2004 Oct
Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats.
2004 Oct
[Preclinical management of accidental methadone intoxication of a 4-year-old girl. Antagonist or intubation?].
2004 Oct
Rapid, transient, and dose-dependent expression of hsp70 messenger RNA in the rat brain after morphine treatment.
2004 Summer
Ventricular tachycardia following naloxone administration in an illicit drug misuse.
2005 Aug
[Effect of naloxone on expression of Bcl-2 protein and tumor necrosis factor-alpha in rats with acute myocardial ischemia/reperfusion injury].
2005 Jul
The opioid fentanyl affects light input, electrical activity and Per gene expression in the hamster suprachiasmatic nuclei.
2005 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells.
2005 Nov
Patents

Sample Use Guides

Opioid Overdose–Known or Suspected: An initial dose of 0.4 mg to 2 mg of NARCAN may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions are not obtained, it may be repeated at two- to three-minute intervals. If no response is observed after 10 mg of NARCAN have been administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available. Postoperative Opioid Depression: For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of NARCAN are usually sufficient. The dose of NARCAN should be titrated according to the patient’s response. For the initial reversal of respiratory depression, NARCAN should be injected in increments of 0.1 to 0.2 mg intravenously at two- to three-minute intervals to the desired degree of reversal, i.e., adequate ventilation and alertness without significant pain or discomfort. Larger than necessary dosage of NARCAN may result in significant reversal of analgesia and increase in blood pressure. Similarly, too rapid reversal may induce nausea, vomiting, sweating or circulatory stress. Repeat doses of NARCAN may be required within one- to two-hour intervals depending upon the amount, type (i.e., short or long acting) and time interval since last administration of an opioid. Supplemental intramuscular doses have been shown to produce a longer lasting effect.
Route of Administration: Other
MDCKII-MDR1 assay. Stock solutions of Naloxone (20 mM) were prepared in 100% DMSO and then diluted to the final concentration of 10 mkM, in Dulbecco’s PBS. Naloxone were tested in both directions, apicalto-basolateral (A→B) and basolateral-to-apical (B→A), in duplicate. The ratio BA/AB >2 indicates an efflux phenomena. Permeability studies were conducted at 37 ◦C in incubator for 60 min. The monolayer integrity was evaluated by measuring the TransEpithelial Electrical Resistance (TEER) by using the Millicell-ERS system (Millipore Corporation) and it was considered integer if the resistancewas between 200 and 300 cm2. After the transport study the monolayer integrity was measured in each well by adding a 0.02 mg/mL solution of lucifer yellow (LY); the test was conducted at 37 ◦C for 60 min, and the fluorescence (RFU) was measured at 485/535 nm.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:44:26 UTC 2023
Edited
by admin
on Wed Jul 05 22:44:26 UTC 2023
Record UNII
36B82AMQ7N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NALOXONE
EMA EPAR   HSDB   INN   MI   ORANGE BOOK   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Common Name English
NALOXONE [MI]
Common Name English
DBL NALOXONE
Brand Name English
Naloxone [WHO-DD]
Common Name English
(-)-N-ALLYL-14-HYDROXYNORDIHYDROMORPHINONE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-(2-PROPENYL)-
Systematic Name English
NALOXONE [VANDF]
Common Name English
NALOXONE [USP-RS]
Common Name English
NALOXONE [EMA EPAR]
Common Name English
NSC-70413
Code English
naloxone [INN]
Common Name English
NALOXONE [ORANGE BOOK]
Common Name English
NALOXONE [HSDB]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 280209
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 4.2
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
NDF-RT N0000000154
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
EMA ASSESSMENT REPORTS SUBOXONE (AUTHORIZED: OPIOID-RELATED DISEASES)
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
WHO-VATC QV03AB15
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
FDA ORPHAN DRUG 79093
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
WHO-ATC V03AB15
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
WHO-ATC A06AH04
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
LIVERTOX NBK548244
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
NDF-RT N0000175691
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
WHO-ATC N02AA53
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
NCI_THESAURUS C681
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL80
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
LACTMED
Naloxone
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
CHEBI
7459
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
PUBCHEM
5284596
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
SMS_ID
100000085468
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
WIKIPEDIA
NALOXONE
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
DRUG CENTRAL
1878
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
RXCUI
7242
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY RxNorm
DAILYMED
36B82AMQ7N
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
EVMPD
SUB09142MIG
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
INN
1526
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID8023349
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
MESH
D009270
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
FDA UNII
36B82AMQ7N
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
DRUG BANK
DB01183
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
NCI_THESAURUS
C62054
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
RS_ITEM_NUM
1453005
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
IUPHAR
1638
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
HSDB
3279
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
207-365-7
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
NSC
70413
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
MERCK INDEX
M7717
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY Merck Index
CAS
465-65-6
Created by admin on Wed Jul 05 22:44:26 UTC 2023 , Edited by admin on Wed Jul 05 22:44:26 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
DERIVATIVE -> PARENT
TARGET -> INHIBITOR
Mu Receptor [3H]DAMGO BINDING INHIBITION
BINDING
Ki
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE LESS ACTIVE -> PARENT
Results also indicate that delay in onset of action of 6-alpha-naloxol at opioid receptors in the central nervous system may contribute significantly to its reduced potency relative to naloxone under certain morphine pretreatment conditions.
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC